ArticleOphthalmology2026
Evaluating the Effectiveness of Escalating to Weekly Adalimumab Dosing for the Treatment of Noninfectious Uveitis: A Multicenter Study.
Article in Ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeTo evaluate the effectiveness of adalimumab dosage escalation in patients with noninfectious uveitis that is controlled inadequately with standard dosing.
designMulticenter retrospective interventional case series.
participantsPatients with noninfectious uveitis receiving active standard biweekly adalimumab dosing who underwent treatment escalation to weekly adalimumab dosing at 6 tertiary referral centers.
methodsDemographic data and clinical findings were assessed at the time of adalimumab dosage escalation and 6 months later. Mixed-model analysis was performed to analyze clinical outcomes and to assess predictive factors of success.
main outcome measuresTreatment success composite criteria included: (1) disease quiescence (≤ 0.5+ anterior chamber cell, ≤ 0.5+ vitreous haze, inactive retinal or choroidal lesions), (2) prednisone 7.5 mg/day or less, and (3) 2 drops/day or less of prednisolone or equivalent (4) no treatment discontinuation.
resultsFifty patients (mean ± standard deviation age, 44.4 ± 21.2 years; n = 35 female patients) from 6 tertiary referral centers were included. At 6 months after adalimumab escalation (median, 184 days), 52% of patients had achieved treatment success. Specific inflammatory signs significantly reduced after adalimumab escalation included anterior chamber cell grade (P = 0.025) and presence of active retinal or choroidal lesions (P = 0.010). Prednisone was decreased from more than 7.5 mg/day to lower dosages in 63% of patients (P = 0.015). The odds ratio for treatment success was 6.88 for patients with posterior uveitis (P = 0.024) and 0.14 (P = 0.005) for patients with panuveitis. The hazard ratio for treatment success was 3.73 (P = 0.009) for eyes with active retinal vasculitis at the time of adalimumab escalation.
conclusionsEscalation from standard biweekly adalimumab dosing to weekly adalimumab dosing achieved treatment success in more than half of the patients. Posterior uveitis predicts a favorable chance of success, whereas panuveitis conveys a lower success rate. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.